Homcy Charles J
SEC-identified person · CIK 1192591 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Bridgebio Pharma, Inc. BBIO | Director · Chairman of Pharmaceuticals | filed 2019 - 2026 |
| Maze Therapeutics, Inc. MAZE | Director | filed 2025 - 2026 |
| Pliant Therapeutics, INC. PLRX | Director | filed 2020 - 2021 |
| Population Health Investment Co., Inc. PHIC | Director | filed 2020 - 2021 |
| Portola Pharmaceuticals INC PTLA | Director | filed 2013 - 2019 |
| Global Blood Therapeutics, Inc. GBT | Director | filed 2015 - 2018 |
| Myokardia, Inc. MYOK | Director | filed 2015 - 2016 |
| Cephalon INC CEPH | Director | filed 2011 - 2011 |
| Geron Corp GERN | Director | filed 2006 - 2011 |
| Cytokinetics INC CYTK | Director | filed 2006 - 2008 |
| Millennium Pharmaceuticals INC MLNM | Director | filed 2006 - 2008 |
| Kosan Biosciences INC KOSN | Director | filed 2006 - 2007 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.